GlassScriptPhysician profile
Mark Jankelow
NPI 1487958070
$287,391.75
in general payments reported to CMS, 2019-2025
26 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57K · 2022: $69K · 2023: $47K · 2024: $52K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $23K · Honoraria: $17K · Food and Beverage: $12K · Consulting Fee: $5,200 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,615.00 |
| Travel and Lodging | $23,306.44 |
| Honoraria | $16,960.50 |
| Food and Beverage | $11,751.15 |
| Consulting Fee | $5,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $650.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $121,016.57 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $52,279.69 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $37,884.00 | 2021-2022 | |
| Axsome Therapeutics, INC. | $26,339.90 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $20,490.03 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $17,264.36 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $5,219.40 | 2024-2025 | Cobenfy |
| Allergan, INC. | $2,266.64 | 2021 | |
| Neurocrine Biosciences, INC. | $1,697.03 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $772.03 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $583.83 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $443.30 | 2021-2025 | Caplyta |
| Lundbeck LLC | $300.57 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $136.98 | 2022-2024 | Quviviq |
| Tris Pharma INC | $135.77 | 2024-2025 | Onyda Xr, Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $128.26 | 2023-2025 | Perseris, Sublocade |
| Eisai INC. | $84.53 | 2021-2022 | |
| Uswm, LLC | $63.49 | 2021-2022 | |
| Braeburn INC. | $58.46 | 2023-2024 | Brixadi |
| Merck Sharp & Dohme LLC | $54.18 | 2022-2023 | Belsomra |
| Avanir Pharmaceuticals, INC. | $48.18 | 2022 | |
| Tempus Ai, INC | $40.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $36.02 | 2022-2024 | Invega Sustenna |
| Almatica Pharma LLC | $18.12 | 2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $15.20 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $14.61 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jankelow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.